Drug intelligence / Profile preview

ZKA3

Development stage: Preclinical
Lead developer: Humabs BioMed
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**ZKA3** is a monoclonal antibody that targets the Zika virus (ZIKV) E protein, specifically recognizing the EDI/II domain. It exhibits partial neutralizing activity against ZIKV infectivity but demonstrates antibody-dependent enhancement (ADE) of infection in FcγR-expressing cells like K562, as well as cross-reactivity with Dengue virus serotype 1 (DENV1), where it similarly neutralizes and enhances infection. Developed initially by Humabs BioMed SA (now part of Vir Biotechnology), it represents an early-stage immunotherapeutic candidate for Zika virus infection amid public health concerns.

Targets

NS1 (Zika virus nonstructural protein 1)

Beyond the preview

Go deeper on ZKA3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZKA3.

Explore the full profile